Andrew Hedin is a Bessemer Venture Partners investor who bridges biotech and mainstream tech by connecting healthcare-native founders with software and consumer-technology founders across the portfolio, arguing that teams with both drug-development expertise and AI/ML skills will win in drug discovery and clinical trials. His background includes pre-clinical neuroscience research and working in a psychology lab for adolescents with anxiety and depression before switching from medicine to healthcare investing, giving him unusually direct exposure to patient psychology and brain science for a venture investor.

• Focuses heavily on the application of artificial intelligence to automate complex administrative workflows within healthcare. He frequently champions Plenful as a prime example of a company using technology to handle tedious back-office tasks for pharmacy and healthcare operators to reduce burnout.
• Enthusiasm for the intersection of machine learning and biotechnology, often referred to as TechBio. He highlighted his investment in Inductive Bio as a solution to the chemical optimization challenges in drug discovery and praised Peptone for their progress in computational biophysics.
• Values founding teams that combine deep scientific knowledge with computational expertise. He looks for these bilingual groups that can bridge the gap between biology and technology, citing the Seismic Tx team as a group that successfully blends drug discovery skills with machine learning capabilities.
• Commitment to precision medicine and therapeutics for rare diseases. He shared his investment thesis for Nido Bio, noting that recent advancements in understanding genetic causes of neuro-related diseases have created a clear opportunity for new treatment developments.
• Promotion of the broader deep tech ecosystem and its benchmarks. He actively shared data from the XB100, a ranking of top private deep tech companies, to discuss trends like valuation and time-to-market for ventures tackling planetary-scale problems.